Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/genie-pharmaceutique/advanced-drug-delivery-strategies-for-targeting-chronic-inflammatory-lung-diseases/descriptif_4693379
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=4693379

Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases , 1st ed. 2022

Langue : Anglais

Coordonnateurs : Chellappan Dinesh Kumar, Pabreja Kavita, Faiyazuddin Md.

Couverture de l’ouvrage Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases

This book describes the growing clinical and healthcare relevance of nano-therapeutics in treating respiratory diseases. It begins with a brief introduction on the different types of nanoparticles in respiratory disease conditions. It further discusses the current trends in understanding the disease pathology using different in vitro and in vivo models, which are important towards the onsite clinical applications and development of new therapeutics. The book includes exciting topics such as formulation of these nanoparticles, targeting various organelles etc. It also describes the future prospects and challenges in the field. Different chapters are written by researchers actively working in the area of pulmonary diseases. This book is designed to address the requirements of both beginners and specialized scientists involved in pulmonary research. The contents include basic concepts followed by advanced state-of-art monitoring and treatment of diseases. The book is meant for researchers and industry experts in nanotechnology, pharmaceutical sciences and drug design.

1. Preface
2. Introduction
2.1. Nanotechnology and its influence
2.2. Novel drug delivery systems
2.3. Significance of nanomaterials in respiratory diseases
3. Nanoparticles in chronic respiratory diseases
3.1. Inflammatory respiratory diseases (Asthma, Chronic obstructive pulmonary disease, Tuberculosis, Lung cancer, Cystic fibrosis)
3.2. Formulation and role of microparticles, microspheres, microemulsions in respiratory diseases
3.3. Formulation and role of polymeric and inorganic nanoparticles
3.4. Liposomes, niosomes, and dendrimers targeting in respiratory diseases
3.5. Micelle targeting in respiratory diseases
4. Targeting immune-system/ cellular level (macrophages & neutrophils) in respiratory diseases using advanced drug delivery systems
5. Mucoadhesive drug delivery system in respiratory diseases
6. Advancement in translational respiratory research using nanotechnology
7. Nanotechnology in pulmonary disease diagnosis
8. Clinical trials using in vitro and in vivo models
9. Targeting biofilms in respiratory diseases using novel drug delivery systems
10. Future prospects and challenges
11. Bibliography
12. Glossary
 

DineshKumarChellappan currently works at the International Medical University (IMU), Kuala Lumpur, Malaysia. He has more than 12 years of teaching experience in the current profession. He completed his Ph.D. in Pharmaceutical Sciences, from the Manipal University, India, in 2009. Prior to that, he did his Master’s in Pharmacy from the same university. He has worked on several research projects, especially in the field of diabetes and inflammation. He has published more than 1200 publications in reputed research journals with a cumulative impact factor of >2400. He also has presented a number of papers at conferences and has received research grants, both at national and international levels, to conduct research. In addition, he is a reviewer and is on the editorial board of several research journals. His area of expertise lies in the preparation of standardized plant extracts, isolation of phytoconstituents, characterization and structural elucidation of phytoconstituents, and pharmacological research of standardized extract for its various activities. 

KavitaPabreja holds a Doctoral degree in Drug Discovery Biology from Monash Institute of Pharmaceutical Sciences, Monash University, Australia. Dr Pabreja’s lecturing experience covers >5 years across national and international Universities, where she actively contributed to medical research and curriculum development. Her research experience includes >10 years of laboratory-based research focuse^21 original research and review articles in high-quality peer-reviewed journals. Currently, Dr Pabreja is utilizing her knowledge and skills in the role of Regulatory Affairs Coordinator with a leading Australian novel vaccine research company.

Md. Faiyazuddin has over 15 years of experience as an entrepreneur, academician, and researcher in the frontier areas of Pharmaceutical Sciences and Nanomedicine. Dr. F

Discusses perspectives and challenges in management and diagnosis of respiratory diseases

Provides insights into drug delivery systems in pulmonary diseases

Includes diagnosis and treatment strategies using controlled drug delivery systems

Date de parution :

Ouvrage de 655 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 105,49 €

Ajouter au panier

Date de parution :

Ouvrage de 655 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 137,14 €

Ajouter au panier